Publications Scientifiques Pr Jean-Jacques Patard. Patard JJ

Publications Scientifiques Pr Jean-Jacques Patard. Patard JJ

Publications Scientifiques Pr Jean-Jacques Patard.
1: Edeline J, Mottier S, Vigneau C, Jouan F, Perrin C, Zerrouki S, Fergelot P, Patard JJ, RiouxLeclercq N. Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma. Hum Pathol.
2012 May 22.
2: Bessede T, Patard JJ. Words of wisdom. Re: Germline mutations in HOXB13 and prostatecancer risk. Eur Urol. 2012 May;61(5):1062.
3: Brassart E, Lebdai S, Berger J, Traore S, Bernhard JC, Fardoun T, Muller G, Patard JJ,
Azzouzi AR, Bigot P. Overall mortality after radical nephrectomy in patients aged over 80 years
with renal cancer: A retrospective study on preoperative prognostic factors. Int J Urol. 2012 Mar
27.
4: Gore ME, Bellmunt J, Eisen T, Escudier B, Mickisch G, Patard JJ, Porta C, Ravaud A,
Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, De Nigris E, Wheeler C, Kirpekar S.
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of
appropriateness, using the validated semi-quantitative RAND corporation/University of California,
Los Angeles methodology. Eur J Cancer. 2012 May;48(7):1038-47.
5: MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P,
Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S, Griffiths TR, Ljungberg B,
N'Dow J; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel.
Systematic review of oncological outcomes following surgical management of localised renal
cancer. Eur Urol. 2012 May;61(5):972-93.
6: Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA,Vetter M,
Jiang M, Saunders RE, Kelly G, Dykema K, Rioux-Leclercq N, Stamp G, Patard JJ, Larkin J,
Howell M, Swanton C. Genome-wide RNA interference analysis of renal carcinoma survival
regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol. 2012 Jun;227(2):146-56.
7: Martin B, Edeline J, Patard JJ, Oger E, Jouan F, Boulanger G, Zerrouki S, Vigneau C, RiouxLeclercq N. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and
endothelial cell lines. J Cancer Res Clin Oncol. 2012 Jun;138(6):907-16.
8: Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD,
Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M,
Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H,
Martínez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG,
Karakiewicz PI, Margulis V. Predicting clinical outcomes after radical nephroureterectomy for
upper tract urothelial carcinoma. Eur Urol. 2012 Apr;61(4):818-25.
9: Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, RiouxLeclerq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Prognostic value
of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in
renal cell carcinoma: a multicenter investigation. J Urol. 2012 Feb;187(2):418-23.
10: Marszalek M, Carini M, Chlosta P, Jeschke K, Kirkali Z, Knüchel R, Madersbacher S, Patard
JJ, Van Poppel H. Positive surgical margins after nephron-sparing surgery. Eur Urol. 2012
Apr;61(4):757-63.
11: Patard JJ, Porta C, Wagstaff J, Gschwend JE. Optimizing treatment for metastatic renal cell
carcinoma. Expert Rev Anticancer Ther. 2011 Dec;11(12):1901-11.
12: Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI,
Staehler M, Sternberg CN, Stief CG. Sequencing of agents for metastatic renal cell carcinoma: can
we customize therapy? Eur Urol. 2012 Feb;61(2):307-16.
13: Perrin C, Patard JJ, Jouan F, Collet N, Théoleyre S, Edeline J, Zerrouki S, Laguerre B,
Bellaud-Roturaud MA, Rioux-Leclercq N, Vigneau C. [The neutrophil gelatinase-associated
lipocalin, or LCN 2, marker of aggressiveness in clear cell renal cell carcinoma]. Prog Urol. 2011
Nov;21(12):851-8.
14: Boulière F, Crepel M, Bigot P, Pignot G, Bessede T, de la Taille A, Salomon L, Tostain J,
Bellec L, Soulié M, Rischmann P, Bernhard JC, Ferrière JM, Pfister C, Albouy B, Colombel M,
Zini L, Villers A, Rigaud J, Bouchot O, Patard JJ. [Nephron-sparing surgery is superior to radical
nephrectomy in preserving renal function outcome in tumors larger than 4 cm]. Prog Urol. 2011
Nov;21(12):842-50.
15: Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, Van Poppel H.
Lymph node dissection in renal cell carcinoma. Eur Urol. 2011 Dec;60(6):1212-20.
16: Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T,
Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J. ICUD-EAU International Consultation
on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011 Oct;60(4):684-90.
17: Bessede T, Pignot G, Patard JJ. Safety issues and rationale for neoadjuvant approaches in
renal cell carcinoma. Eur Urol. 2011 Nov;60(5):972-4.
18: Volpe A, Cadeddu JA, Cestari A, Gill IS, Jewett MA, Joniau S, Kirkali Z, Marberger M,
Patard JJ, Staehler M, Uzzo RG. Contemporary management of small renal masses. Eur Urol.
2011 Sep;60(3):501-15.
19: Rouprêt M, Drouin SJ, Larré S, Neuzillet Y, Botto H, Hitier M, Rigaud J, Crew J, Xylinas E,
Salomon L, Cornu JN, Iborra F, Champetier D, Rozet F, Flamand V, Bastide C, Cormier L, Durand
X, Lunardi P, Rischmann P, Nouhaud FX, Ferlicot S,Patard JJ, Floch AP, Irani J, Peyronnet B,
Bensalah K, Poissonnier L, Grès P, Droupy S, Casenave J, Wallerand H, Soulié M, Pfister C;
Bladder Cancer Committee of the French National Association of Urology (“CC-AFU Vessie”).
Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without
neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol.
2011 Dec;18(13):3833-8.
20: Bessede T, Bigot P, Neuzillet Y, Pignot G, Patard JJ, Pfister Ch, Rigaud J, Salomon L, Soulié
M. [The 2010 news: highlights of the ASCO-GU, UAE, ASCO, AUA congress…]. Prog Urol.
2011 Mar;21 Suppl 2:S16-22.
21: Neuzillet Y, Tillou X, Mathieu R, Long JA, Gigante M, Paparel P, Poissonnier L, Baumert H,
Escudier B, Lang H, Rioux-Leclercq N, Bigot P, Bernhard JC, Albiges L, Bastien L, Petit J, Saint
F, Bruyere F, Boutin JM, Brichart N, Karam G, Branchereau J, Ferriere JM, Wallerand H, Barbet
S, Elkentaoui H, Hubert J, Feuillu B, Theveniaud PE, Villers A, Zini L, Descazeaux A, Roupret M,
Barrou B, Fehri K, Lebret T, Tostain J, Terrier JE, Terrier N, Martin L, Dugardin F, Galliot I,
Staerman F, Azemar MD, Irani J, Tisserand B, Timsit MO, Sallusto F, Rischmann P, Guy L, Valeri
A, Deruelle C, Azzouzi AR, Chautard D, Mejean A, Salomon L, Rigaud J, Pfister C, Soulié M,
Kleinclauss F, Badet L, Patard JJ; Comité de Transplantation de l'Association Française
d'Urologie; Comité de Cancérologie de l'Association Française d'Urologie. Renal cell carcinoma
(RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and
outcome features compared with RCC in the general population. Eur Urol. 2011 Aug;60(2):366-73.
22: Thuret R, Sun M, Abdollah F, Schmitges J, Shariat SF, Iborra F, Guiter J, Patard JJ, Perrotte
P, Karakiewicz PI. Conditional survival predictions after surgery for patients with penile
carcinoma. Cancer. 2011 Aug 15;117(16):3723-30.
23: Bessede T, Massard C, Albouy B, Leborgne S, Gross-Goupil M, Droupy S, Patard JJ, Fizazi K,
Escudier B. Sexual life of male patients with advanced renal cancer treated with angiogenesis
inhibitors. Ann Oncol. 2011 Oct;22(10):2320-4.
24: Bensalah K, Patard JJ. Kidney cancer in 2010: drugs, surgery and survival in RCC. Nat Rev
Urol. 2011 Feb;8(2):66-8.
25: Maubec E, Chaudru V, Mohamdi H, Grange F, Patard JJ, Dalle S, Crickx B, Paillerets BB,
Demenais F, Avril MF. Characteristics of the coexistence of melanoma and renal cell carcinoma.
Cancer. 2010 Dec 15;116(24):5716-24.
26: Collet N, Théoleyre S, Rageul J, Mottier S, Jouan F, Rioux-Leclercq N, Fergelot P, Patard JJ,
Masson D, Denis MG. PPARγ is functionally expressed in clear cell renal cell carcinoma. Int J
Oncol. 2011 Mar;38(3):851-7.
27: Verhoest G, Patard JJ, Delreux A, Crepel M, Manunta A, Vincendeau S, Guille F, Bensalah
K. [Renal LESS surgery: Slight modification or surgical revolution?]. Prog Urol. 2011
Jan;21(1):29-33.
28: Thuret R, Sun M, Abdollah F, Budaus L, Lughezzani G, Liberman D, Morgan M, Johal R,
Jeldres C, Latour M, Shariat SF, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI. Tumor
grade improves the prognostic ability of American Joint Committee on Cancer stage in patients
with penile carcinoma. J Urol. 2011 Feb;185(2):501-7.
29: Paparel P, Bessede T, Patard JJ. Is robot-assisted partial nephrectomy already mature for
challenging cases? Eur Urol. 2011 Mar;59(3):331-2.
30: Mathieu R, Patard JJ, Stock N, Rioux-Leclercq N, Guillé F, Fergelot P, Bensalah K. [Study of
the expression of Aurora kinases in renal cell carcinoma]. Prog Urol. 2010 Dec;20(13):1200-5.
31: Patard JJ, Baumert H, Corréas JM, Escudier B, Lang H, Long JA, Neuzillet Y, Paparel P,
Poissonnier L, Rioux-Leclercq N, Soulié M; Oncology Committee of the French Association of
Urology (CCAFU). [Recommendations Onco-Urology 2010: Kidney cancer]. Prog Urol. 2010
Nov;20 Suppl 4:S319-39.
32: Rébillard X, Grosclaude P, Lebret T, Patard JJ, Pfister C, Richaud P, Rigaud J, Salomon L,
Soulié M. [Projected incidence and mortality from urologic cancer in France in 2010.]. Prog Urol.
2010 Nov;20 Suppl 4:S211-4.
33: Soulié M, Coloby P, Irani J, Lebret T, Patard JJ, Pfister C, Richaud P, Rigaud J, Salomon L.
[Recommendations of good clinical practice: diagnosis, treatment and monitoring of urological
cancers in men and women.]. Prog Urol. 2010 Nov;20 Suppl 4:S205-7.
34: Dolley-Hitze T, Jouan F, Martin B, Mottier S, Edeline J, Moranne O, Le Pogamp P, BelaudRotureau MA, Patard JJ, Rioux-Leclercq N, Vigneau C. Angiotensin-2 receptors (AT1-R and
AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer. 2010 Nov
23;103(11):1698-705.
35: Wallerand H, Robert G, Bernhard JC, Ravaud A, Patard JJ. Tyrosine-kinase inhibitors in the
treatment of muscle invasive bladder cancer and hormone refractory prostate cancer. Arch Esp
Urol. 2010 Nov;63(9):773-87.
36: Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, Shariat SF, Montorsi F,
Patard JJ, Perrotte P, Karakiewicz PI. Age-adjusted incidence, mortality, and survival rates of
stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011
Jan;59(1):135-41.
37: Prunel P, Verhoest G, Boudry G, Rohou T, Bouget J, Patard JJ, Guillé F, Bensalah K. [Impact
of low-dose CT in the diagnosis and treatment of renal colic in emergency department]. Prog Urol.
2010 Oct;20(9):633-7.
38: Verhoest G, Patard JJ, Fergelot P, Jouan F, Zerrouki S, Dreano S, Mottier S, Rioux-Leclercq
N, Denis MG. Paraffin-embedded tissue is less accurate than frozen section analysis for
determining VHL mutational status in sporadic renal cell carcinoma. Urol Oncol. 2010 Sep 20.
39: Thuret R, Sun M, Lughezzani G, Budaus L, Liberman D, Abdollah F, Morgan M, Johal R,
Jeldres C, Latour M, Shariat SF, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI. A
contemporary population-based assessment of the rate of lymph node dissection for penile
carcinoma. Ann Surg Oncol. 2011 Feb;18(2):439-46.
40: Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T, van
Poppel H, Wood CG. Integrating surgery with targeted therapies for renal cell carcinoma: current
evidence and ongoing trials. Eur Urol. 2010 Dec;58(6):819-28.
41: Bensalah K, Fleureau J, Rolland D, Rioux-Leclercq N, Senhadji L, Lavastre O, Guillé F,
Patard JJ, de Crevoisier R. [Optical spectroscopy: a new approach to assess urological tumors].
Prog Urol. 2010 Jul;20(7):477-82.
42: Pignot G, Boulière F, Patard JJ. Warm ischaemia: the ultimate enemy for partial
nephrectomy? Eur Urol. 2010 Sep;58(3):337-9.
43: Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ,
Mulders PF, Sinescu IC; European Association of Urology Guideline Group. EAU guidelines on
renal cell carcinoma: the 2010 update. Eur Urol. 2010 Sep;58(3):398-406.
44: Shuch B, Crispen PL, Leibovich BC, Larochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M,
Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML.
Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep
hypothermic circulatory arrest limit perioperative mortality? BJU Int. 2011 Mar;107(5):724-8.
45: Bensalah K, Fleureau J, Rolland D, Lavastre O, Rioux-Leclercq N, Guillé F, Patard JJ,
Senhadji L, de Crevoisier R. Raman spectroscopy: a novel experimental approach to evaluating
renal tumours. Eur Urol. 2010 Oct;58(4):602-8.
46: Zisman A, Patard JJ, Raz O, Klatte T, Haifler M, Mendlovic S, Sandbank J, Belldegrun AS,
Lindner A, Leibovici D, Pantuck AJ. Sex, age, and surgeon decision on nephron-sparing surgery
are independent predictors of renal masses with benign histologic findings--a multicenter survey.
Urology. 2010 Sep;76(3):541-6.
47: Patard JJ, Escudier B, Paparel P, Neuzillet Y, Long JA, Baumert H, Correas JM, Lang H,
Poissonnier L, Rioux-Leclercq N, Soulié M; le Comité de Cancérologie de l'Association Française
d'Urologie (CCAFU). [Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO
about the medical management of locally advanced or metastatic kidney cancer]. Prog Urol. 2010
Mar;20 Suppl 1:S11-5.
48: Bigot P, Bernhard JC, Crepel M, Bensalah K, Azzouzi AR, de la Taille A, Salomon L, Tostain
J, Ficarra V, Pantuck AJ, Belldegrun AS, Méjean A, Ferrière JM, Pfister C, Albouy B, Colombel
M, Zini L, Villers A, Montorsi F, Shariat S, Rioux-Leclercq N, Patard JJ. [How radical
nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell
carcinomas?]. Prog Urol. 2010 May;20(5):350-5.
49: Wheat JC, Weizer AZ, Wolf JS Jr, Lotan Y, Remzi M, Margulis V, Wood CG, Montorsi F,
Roscigno M, Kikuchi E, Zigeuner R, Langner C, Bolenz C, Koppie TM, Raman JD, Fernández M,
Karakiewizc P, Capitanio U, Bensalah K, Patard JJ, Shariat SF. Concomitant carcinoma in situ is
a feature of aggressive disease in patients with organ confined urothelial carcinoma following
radical nephroureterectomy. Urol Oncol. 2012 May;30(3):252-8.
50: Paparel P, Long JA, Baumert H, Meyer V, Escudier B, Grenier N, Hetet JF, Rioux-Leclercq N,
Lang H, Poissonier L, Soulie M, Patard JJ. [Current role of lymph node dissection in renal cell
carcinoma: Review of the literature by the Oncology Committee of the French Association of
Urology (CCAFU)]. Prog Urol. 2010 May;22(6):313-7.
51: Edeline J, Vigneau C, Patard JJ, Rioux-Leclercq N. [Signalling pathways in renal-cell
carcinoma: from the molecular biology to the future therapy]. Bull Cancer. 2010;97:5-15.
52: Pouessel D, Patard JJ, Culine S. [Advanced renal carcinomas with special situations. How to
treat them?]. Bull Cancer. 2010;97:83-90.
53: Bigot P, Lughezzani G, Bensalah K, Rioux-Leclercq N, Guillé F, Lobel B, Moulinoux JP,
Catros-Quemener V, Cipolla B, Azzouzi AR, Karakiewicz P, Patard JJ.[Prognostic value of
erythrocyte polyamines levels in renal cell carcinoma. Prospective study in 418 cases]. Prog Urol.
2010 Apr;20(4):272-8.
54: Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol. 2010
Jun;28(3):319-27.
55: Lughezzani G, Karakiewicz PI, Bigot P, Perrotte P, Crépel M, Rioux-Leclercq N, CatrosQuemener V, Moulinoux JP, Bouet F, Cipolla B, Patard JJ. The prognostic value of erythrocyte
polyamines in the preoperative evaluation of patients with renal cell carcinoma. Eur J Cancer. 2010
Jul;46(10):1927-35.
56: Masson D, Rioux-Leclercq N, Fergelot P, Jouan F, Mottier S, Théoleyre S, Bach-Ngohou K,
Patard JJ, Denis MG. Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur J
Cancer. 2010 May;46(8):1430-7.
57: Bernhard JC, Pantuck AJ, Wallerand H, Crepel M, Ferrière JM, Bellec L, Maurice-Tison S,
Robert G, Albouy B, Pasticier G, Soulie M, Lopes D, Lacroix B, Bensalah K, Pfister C, Thuret R,
Tostain J, De La Taille A, Salomon L, Abbou C, Colombel M, Belldegrun AS, Patard JJ.
Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma.
Eur Urol. 2010 Jun;57(6):1080-6.
58: Mottet N, Lebret T, Patard JJ, Pfister C, Rigaud J, Salomon L, Soulié M. [Does cancer surgery
in elderly patients present special issues?]. Prog Urol. 2009 Nov;19 Suppl 3:S93-5.
59: Soulié M, Lebret T, Patard JJ, Pfister C, Richaud P, Rigaud J, Salomon L. [Role of the
multidisciplinary structured and adjusted management...]. Prog Urol. 2009 Nov;19 Suppl 3:S65-6.
60: Escudier B, Paparel P, Neuzillet Y, Long JA, Rioux-Leclercq N, Correas JM, Lang H,
Poissonnier L, Baumert H, Mejean A, Patard JJ. [Treatment of metastatic kidney cancer in elderly
subjects]. Prog Urol. 2009 Nov;19 Suppl 3:S129-32.
61: Paparel P, Long JA, Neuzillet Y, Escudier B, Rioux-Leclercq N, Correas JM, Lang H,
Poissonnier L, Baumert H, Mejean A, Soulié M, Patard JJ. [The place of laparoscopic
nephrectomy in the elderly subject]. Prog Urol. 2009 Nov;19 Suppl 3:S124-8.
62: Long JA, Neuzillet Y, Poissonnier L, Lang H, Paparel P, Escudier B, Rioux-Leclercq N,
Correas JM, Mejean A, Baumert H, Soulié M, Patard JJ. [Do ablative treatments modify the
management of kidney tumors in the elderly?]. Prog Urol. 2009 Nov;19 Suppl 3:S116-23.
63: Baillargeon-Gagné S, Jeldres C, Lughezzani G, Sun M, Isbarn H, Capitanio U, Shariat SF,
Crépel M, Alasker A, Widmer H, Arjane P, Patard JJ, Perrotte P, Montorsi F, Graefen M,
Karakiewicz PI. A comparative population-based analysis of the rate of partial vs radical
nephrectomy for clinically localized renal cell carcinoma. BJU Int. 2010 Feb;105(3):359-64.
64: Bigot P, Lughezzani G, Karakiewicz P, Perrotte P, Rioux-Leclercq N, Catros-Quemener V,
Bouet F, Moulinoux JP, Cipolla B, Patard JJ. The prognostic value of erythrocyte polyamine in
the post-nephrectomy stratification of renal cell carcinoma specific mortality. J Urol. 2010
Feb;183(2):486-91.
65: Crépel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, Shariat SF, Liberman D, Sun M,
Lughezzani G, Arjane P, Widmer H, Graefen M, Montorsi F, Patard JJ, Karakiewicz PI. Nephronsparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a
population-based assessment. Urology. 2010 Feb;75(2):271-5.
66: Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi
M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ,
Fernández MI, Wood CG, Montorsi F, Ströbel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C,
Chade DC, Sagalowsky A, Langner C. Tumour necrosis is an indicator of aggressive biology in
patients with urothelial carcinoma of the upper urinary tract. Eur Urol. 2010 Apr;57(4):575-81.
67: Edeline J, Laguerre B, Rolland Y, Patard JJ. Aortic dissection in a patient treated by sunitinib
for metastatic renal cell carcinoma. Ann Oncol. 2010 Jan;21(1):186-7.
68: Touijer K, Jacqmin D, Kavoussi LR, Montorsi F, Patard JJ, Rogers CG, Russo P, Uzzo RG,
Van Poppel H. The expanding role of partial nephrectomy: a critical analysis of indications, results,
and complications. Eur Urol. 2010 Feb;57(2):214-22.
69: Jeldres C, Sun M, Liberman D, Lughezzani G, de la Taille A, Tostain J, Valeri A, Cindolo L,
Ficarra V, Artibani W, Zigeuner R, Mejean A, Descotes JL, Lechevallier E, Mulders PF, Perrotte P,
Patard JJ, Karakiewicz PI. Can renal mass biopsy assessment of tumor grade be safely substituted
for by a predictive model? J Urol. 2009 Dec;182(6):2585-9.
70: Karakiewicz PI, Suardi N, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V,
Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck AJ, Belldegrun AS, Zini L, de la Taille A,
Chautard D, Descotes JL, Shariat SF, Valeri A, Mulders PF, Lang H, Lechevallier E, Patard JJ.
Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol. 2009
Dec;182(6):2607-12.
71: Isbarn H, Patard JJ, Lughezzani G, Rioux-Leclercq N, Crépel M, Cindolo L, de la Taille A,
Zini L, Villers A, Shariat SF, Bertini R, Karakiewicz PI. Limited prognostic value of tumor
necrosis in patients with renal cell carcinoma. Urology. 2010 Jun;75(6):1378-84.
72: Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, Collet N, Dubourg C, Lobel B,
Denis M, Fergelot P. Absence of VHL gene alteration and high VEGF expression are associated
with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer. 2009 Oct
20;101(8):1417-24.
73: Patard JJ. Toward standardized anatomical classifications of small renal tumors. Eur Urol.
2009 Nov;56(5):794-5.
74: Neuzillet Y, Long JA, Paparel P, Baumert H, Correas JM, Escudier B, Lang H, Poissonnier L,
Rioux-Leclercq N, Salomon L, Soulie M, Patard JJ; le Comité de cancérologie de l'Association
française d'urologie (CCAFU). [Clamping modalities during partial nephrectomy: technical aspects
and functional consequences. Review by the Comité de cancérologie de l'Association française
d'urologie (CCAFU)]. Prog Urol. 2009 Sep;19(8):524-9
75: Lughezzani G, Jeldres C, Isbarn H, Perrotte P, Shariat SF, Sun M, Widmer H, Arjane P,
Peloquin F, Pharand D, Patard JJ, Graefen M, Montorsi F, Karakiewicz PI. Tumor size is a
determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol. 2009
Oct;182(4):1287-93.
76: Neuzillet Y, Culine S, Patard JJ. Prognostic factors for cases with metastatic renal cell
carcinoma in the era of targeted medicine. Int J Urol. 2009 Nov;16(11):855-61.
77: Crépel M, Isbarn H, Capitanio U, Liberman D, Jeldres C, Sun M, Shariat SF, Widmer H,
Arjane P, Graefen M, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI. Does histologic subtype
affect oncologic outcomes after nephron-sparing surgery? Urology. 2009 Oct;74(4):842-5.
78: Bensalah K, Salomon L, Lang H, Zini L, Jacqmin D, Manunta A, Crepel M,
Ficarra V, Cindolo L, de La Taille A, Karakiewicz P, Patard JJ. Survival of
patients with nonmetastatic pT3 renal tumours: a matched comparison of
laparoscopic vs open radical nephrectomy. BJU Int. 2009 Dec;104(11):1714-7.
79: Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E,
Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi
M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M,
Karakiewcz P, Shariat SF. Impact of tumor location on prognosis for patients with upper tract
urothelial carcinoma managed by radical nephroureterectomy. Eur Urol. 2010 Jun;57(6):1072-9.
80: Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, Tostain J, Guille F,
Cindolo L, De La Taille A, Abbou CC, Salomon L, Rioux-Leclercq N, Patard JJ. Urinary
collecting system invasion is an independent prognostic factor of organ confined renal cell
carcinoma. J Urol. 2009 Sep;182(3):854-9.
81: Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG,
Sulser T, Wild PJ. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur
Urol. 2009 Oct;56(4):636-43.
82: Sun M, Lughezzani G, Jeldres C, Isbarn H, Shariat SF, Arjane P, Widmer H, Pharand D, Latour
M, Perrotte P, Patard JJ, Karakiewicz PI. A proposal for reclassification of the Fuhrman grading
system in patients with clear cell renal cell carcinoma. Eur Urol. 2009 Nov;56(5):775-81.
83: Patard JJ. Incidental renal tumours. Curr Opin Urol. 2009 Sep;19(5):454-8.
84: Rogers CG, Patard JJ. Open to debate. The motion: Robotic partial nephrectomy is better than
open partial nephrectomy. Eur Urol. 2009 Sep;56(3):568-70.
85: Jeldres C, Bensalah K, Capitanio U, Zini L, Perrotte P, Suardi N, Tostain J, Valeri A, Descotes
JL, Rambeaud JJ, de La Taille A, Salomon L, Abbou C, Patard JJ, Karakiewicz PI. Baseline renal
function, ischaemia time and blood loss predict the rate of renal failure after partial nephrectomy.
BJU Int. 2009
86: Phé V, Rouprêt M, Lechevallier E, Patard JJ. [What's new in 2008 in kidney cancer?]. Prog
Urol. 2009 May;19 Suppl 2:S56-64.
87: Jeldres C, Patard JJ, Capitanio U, Perrotte P, Suardi N, Crepel M, Ficarra V, Cindolo L, de La
Taille A, Tostain J, Pfister C, Albouy B, Colombel M, Méjean A, Lang H, Jacqmin D, Bernhard
JC, Ferrière JM, Bensalah K, Karakiewicz PI. Partial versus radical nephrectomy in patients with
adverse clinical or pathologic characteristics. Urology. 2009 Jun;73(6):1300-5.
88: Bensalah K, Pantuck AJ, Rioux-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI, Mottet N,
Zini L, Bertini R, Salomon L, Villers A, Soulie M, Bellec L, Rischmann P, De la Taille A, Avakian
R, Crepel M, Ferriere JM, Bernhard JC, Dujardin T, Pouliot F, Rigaud J, Pfister C, Albouy B, Guy
L, Joniau S, van Poppel H, Lebret T, Culty T, Saint F, Zisman A, Raz O, Lang H, Spie R, Wille A,
Roigas J, Aguilera A, Rambeaud B, Martinez Piñeiro L, Nativ O, Farfara R, Richard F, Roupret M,
Doehn C, Bastian PJ, Muller SC, Tostain J, Belldegrun AS, Patard JJ. Positive surgical margin
appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing
surgery. Eur Urol. 2010 Mar;57(3):466-71.
89: Letang N, Cabaniols L, Pouessel D, Robert M, Iborra F, Culine S, Patard JJ, Guiter J, Thuret
R. [Prognostic factors in renal cell carcinoma]. Bull Cancer. 2009 Apr;96(4):475-84.
90: Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A. Targeted therapies in
metastatic renal cancer in 2009. BJU Int. 2009 May;103(10):1334-42.
91: Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, Saad F, Patard JJ, Montorsi
F, Karakiewicz PI. Radical versus partial nephrectomy: effect on overall and noncancer mortality.
Cancer. 2009 Apr 1;115(7):1465-71.
92: Patard JJ. Editorial comment on: En bloc mobilization of the pancreas and spleen to facilitate
resection of large tumors, primarily renal and adrenal, in the left upper quadrant of the abdomen:
techniques derived from multivisceral transplantation. Eur Urol. 2009 May;55(5):1111.
93: Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A,
Raman JD, Wood CG; Upper Tract Urothelial Carcinoma CollaborationThe Upper Tract Urothelial
Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract
Urothelial Carcinoma Collaboration. Cancer. 2009 Mar 15;115(6):1224-33.
94: Zini L, Perrotte P, Jeldres C, Capitanio U, Duclos A, Jolivet-Tremblay M, Arjane P, Péloquin
F, Pharand D, Villers A, Montorsi F, Patard JJ, Karakiewicz PI. A population-based comparison
of survival after nephrectomy vs nonsurgical management for small renal masses. BJU Int. 2009
Apr;103(7):899-904;
95: Long JA, Neuzillet Y, Correas JM, de Fromont M, Lang H, Mejean A, Poissonnier L, Patard
JJ, Escudier B, Davin JL; Sous-comité rein CCAFU. [Atypical cysts and cystic tumours of the
kidney: histological, radiological and surgical considerations. Conclusions of the AFU 2007
forum]. Prog Urol. 2009 Jan;19(1):8-14
96: Capitanio U, Cloutier V, Zini L, Isbarn H, Jeldres C, Shariat SF, Perrotte P, Antebi E, Patard
JJ, Montorsi F, Karakiewicz PI. A critical assessment of the prognostic value of clear cell,
papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study.
BJU Int. 2009 Jun;103(11):1496-500.
97: Zini L, Patard JJ, Capitanio U, Crepel M, de La Taille A, Tostain J, Ficarra V, Bernhard JC,
Ferrière JM, Pfister C, Villers A, Montorsi F, Karakiewicz PI. Cancer-specific and non-cancerrelated mortality rates in European patients with T1a and T1b renal cell carcinoma. BJU Int. 2009
Apr;103(7):894-8.
98: Karakiewicz PI, Jeldres C, Suardi N, Hutterer GC, Perrotte P, Capitanio U, Ficarra V, Cindolo
L, de La Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Schips L, Chautard D, Valeri A,
Lechevallier E, Descotes JL, Lang H, Mejean A, Verhoest G, Patard JJ. Age at diagnosis is a
determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy.
Can Urol Assoc J. 2008 Dec;2(6):610-7.
99: Cloutier V, Capitanio U, Zini L, Perrotte P, Jeldres C, Shariat SF, Arjane P, Patard JJ,
Montorsi F, Karakiewicz PI. Thirty-day mortality after nephrectomy: clinical implications for
informed consent. Eur Urol. 2009 Dec;56(6):998-1003.
100: Novara G, De Marco V, Dalpiaz O, Galfano A, Bouygues V, Gardiman M, Martignoni G,
Patard JJ, Artibani W, Ficarra V. Independent predictors of contralateral metachronous upper
urinary tract transitional cell carcinoma after nephroureterectomy: multi-institutional dataset from
three European centers. Int J Urol. 2009 Feb;16(2):187-91.
101: Zini L, Capitanio U, Perrotte P, Jeldres C, Shariat SF, Arjane P, Widmer H, Montorsi F,
Patard JJ, Karakiewicz PI. Population-based assessment of survival after cytoreductive
nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology. 2009
Feb;73(2):342-6.
102: Patard JJ, Lechevallier E, Descazeaud A. [Kidney cancer: news in 2008]. Prog Urol. 2008
Sep;18 Suppl 6:S135-40.
103: Zini L, Perrotte P, Capitanio U, Jeldres C, Duclos A, Arjane P, Villers A, Montorsi F, Patard
JJ, Karakiewicz PI. Race affects access to nephrectomy but not survival in renal cell carcinoma.
BJU Int. 2009 Apr;103(7):889-93.
104: Capitanio U, Jeldres C, Patard JJ, Perrotte P, Zini L, de La Taille A, Ficarra V, Cindolo L,
Bensalah K, Artibani W, Tostain J, Valeri A, Zigeuner R, Méjean A, Descotes JL, Lechevallier E,
Mulders PF, Lang H, Jacqmin D, Karakiewicz PI. Stage-specific effect of nodal metastases on
survival in patients with non-metastatic renal cell carcinoma. BJU Int. 2009 Jan;103(1):33-7.
105: Cornu JN, Rouprêt M, Lang H, Long JA, Neuzillet Y, Patard JJ, Piéchaud T, Corréas JM, de
Fromont M, Escudier B, Méjean A. [Kidney cancer management in 2007: news and
recommendations]. Prog Urol. 2008 Jul;18 Suppl 4:S81-7.
106: Oudard S, Cornu JN, Rouprêt M, Patard JJ. [Antiangiogenic treatment and kidney cancer:
ongoing trials and future perspectives]. Prog Urol. 2008 Jul;18 Suppl 4:S77-80.
107: Cornu JN, Rouprêt M, Bensalah K, Oudard S, Patard JJ. [Antiangiogenics: new therapeutic
standards in metastatic kidney cancer]. Prog Urol. 2008 Jul;18 Suppl 4:S69-76.
108: Patard JJ, Thuret R, Raffi A, Laguerre B, Bensalah K, Culine S. Treatment with sunitinib
enabled complete resection of massive lymphadenopathy not previously amenable to excision in a
patient with renal cell carcinoma. Eur Urol. 2009 Jan;55(1):237-9;
109: Capitanio U, Zini L, Perrotte P, Shariat SF, Jeldres C, Arjane P, Pharand D, Widmer H,
Péloquin F, Montorsi F, Patard JJ, Karakiewicz PI. Cytoreductive partial nephrectomy does not
undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology.
2008 Nov;72(5):1090-5.
110: Zini L, Patard JJ, Capitanio U, Mejean A, Villers A, de La Taille A, Ficarra V, Crepel M,
Bertini R, Salomon L, Verhoest G, Perrotte P, Bensalah K, Arjane P, Biserte J, Montorsi F,
Karakiewicz P. The use of partial nephrectomy in European tertiary care centers. Eur J Surg
Oncol. 2009 Jun;35(6):636-42.
111: Crépel M, Bensalah K, Patard JJ. [Does tumour diameter still limit the indications for partial
nephrectomy in 2008?]. Prog Urol. 2008 Sep;18(8):487-92.
112: Bensalah K, Pantuck AJ, Crepel M, Verhoest G, Méjean A, Valéri A, Ficarra V, Pfister C,
Ferrière JM, Soulié M, Cindolo L, De La Taille A, Tostain J, Chautard D, Schips L, Zigeuner R,
Abbou CC, Lobel B, Salomon L, Lechevallier E, Descotes JL, Guillé F, Colombel M, Belldegrun
AS, Patard JJ. Prognostic variables to predict cancer-related death in incidental renal tumours.
BJU Int. 2008 Nov;102(10):1376-80.
113: Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L, de la Taille A,
Tostain J, Mulders PF, Bensalah K, Artibani W, Salomon L, Zigeuner R, Valéri A, Descotes JL,
Rambeaud JJ, Méjean A, Montorsi F, Bertini R, Patard JJ. A preoperative prognostic model for
patients treated with nephrectomy for renal cell carcinoma. Eur Urol. 2009 Feb;55(2):287-95.
114: Zini L, Perrotte P, Jeldres C, Capitanio U, Pharand D, Arjane P, Lapointe S, Montorsi F,
Patard JJ, Karakiewicz PI. Nephrectomy improves the survival of patients with locally advanced
renal cell carcinoma. BJU Int. 2008 Dec;102(11):1610-4.
115: Wagner B, Patard JJ, Méjean A, Bensalah K, Verhoest G, Zigeuner R, Ficarra V, Tostain J,
Mulders P, Chautard D, Descotes JL, de la Taille A, Salomon L, Prayer-Galetti T, Cindolo L,
Valéri A, Meyer N, Jacqmin D, Lang H. Prognostic value of renal vein and inferior vena cava
involvement in renal cell carcinoma. Eur Urol. 2009 Feb;55(2):452-9
116: Patard JJ, Pouessel D, Culine S. New therapies in renal cell carcinoma. Curr Opin Support
Palliat Care. 2007 Oct;1(3):174-9.
117: Bernhard JC, Ferriere JM, Crepel M, Wallerand H, Bellec L, Lacroix B, Lopes D, Albouy B,
Robert G, Ravaud A, Colombel M, Tostain J, Pfister C, Soulie M, Salomon L, De La Taille A,
Pasticier G, Abbou CC, Manunta A, Guille F, Patard JJ. [What is the clinical practice of partial
nephrectomy in France?]. Prog Urol. 2008 Jul;18(7):428-34.
118: Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, Salomon L,
Allory Y, Vordos D, Hoznek A, Yiou R, Patard JJ, Abbou CC, de la Taille A. Prostate cancer
detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol. 2009
Mar;55(3):600-6.
119: Le Tortorec A, Denis H, Satie AP, Patard JJ, Ruffault A, Jégou B, Dejucq-Rainsford N.
Antiviral responses of human Leydig cells to mumps virus infection or poly I:C stimulation. Hum
Reprod. 2008 Sep;23(9):2095-103.
120: Ferhi K, Lakehal M, Avakian R, Bensallah K, Boudjema K, Patard JJ, Guille F. [Combined
liver-kidney transplantation: indications and results]. Prog Urol. 2008 Apr;18(4):245-50.
121: Verhoest G, Crepel M, Bernhard JC, Bellec L, Albouy B, Lopes D, Lacroix B, De La Taille A,
Salomon L, Pfister C, Soulié M, Tostain J, Ferrière JM, Abbou CC, Colombel M, Vincendeau S,
Bensalah K, Manunta A, Guillé F, Patard JJ. [Do broader indications for partial nephrectomy
result in excess morbidity?]. Prog Urol. 2008 Apr;18(4):207-13.
122: Neuzillet Y, Correas JM, Escudier B, de Fromont M, Lang H, Long JA, Patard JJ,
Poissonnier L, Mejean A; le Comité de cancérologie de l'Association française d'urologie. [What
may be the waiting time between the diagnosis and surgical treatment of kidney cancer?]. Prog
Urol. 2008 Apr;18(4):197-203.
123: Patard JJ. Editorial comment on: The impact of temporal presentation on clinical and
pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol. 2008
Oct;54(4):864.
124: Ravaud A, Wallerand H, Culine S, Bernhard JC, Fergelot P, Bensalah K, Patard JJ. Update
on the medical treatment of metastatic renal cell carcinoma. Eur Urol. 2008 Aug;54(2):315-25.
125: Cindolo L, Chiodini P, Gallo C, Ficarra V, Schips L, Tostain J, de La Taille A, Artibani W,
Patard JJ. Validation by calibration of the UCLA integrated staging system prognostic model for
nonmetastatic renal cell carcinoma after nephrectomy. Cancer. 2008 Jul 1;113(1):65-71.
126: Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, Said JW,
Belldegrun AS, Pantuck AJ. Low CAIX expression and absence of VHL gene mutation are
associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J
Cancer. 2008 Jul 15;123(2):395-400.
127: Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ,
Belldegrun AS. Neoadjuvant targeted therapy and advanced kidney cancer: observations and
implications for a new treatment paradigm. BJU Int. 2008 Sep;102(6):692-6.
128: Galfano A, Novara G, Iafrate M, Cavalleri S, Martignoni G, Gardiman M, D'Elia C, Patard
JJ, Artibani W, Ficarra V. Mathematical models for prognostic prediction in patients with renal
cell carcinoma. Urol Int. 2008;80(2):113-23.
129: Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, Abbou CC,
Allhoff EP, Carrieri G, Riggs SB, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Tumor size does not
predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol. 2008
May;179(5):1719-26.
130: Patard JJ, Pouessel D, Bensalah K, Culine S. Targeted therapy in renal cell carcinoma.
World J Urol. 2008 Apr;26(2):135-40.
131: Novara G, De Marco V, Dalpiaz O, Gottardo F, Bouygues V, Galfano A, Martignoni G,
Patard JJ, Artibani W, Ficarra V. Independent predictors of metachronous bladder transitional cell
carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int. 2008
Jun;101(11):1368-74.
132: Sarkissian G, Fergelot P, Lamy PJ, Patard JJ, Culine S, Jouin P, Rioux-Leclercq N,
Darbouret B. Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of
proteomic analysis. Clin Chem. 2008 Mar;54(3):574-81.
133: Patard JJ. Editorial comment on: impact of gender in renal cell carcinoma: an analysis of the
SEER database. Eur Urol. 2008 Jul;54(1):141-2
134: Mejean A, Correas JM, Escudier B, de Fromont M, Lang H, Long JA, Neuzillet Y, Patard JJ,
Piechaud T. [Kidney tumors]. Prog Urol. 2007 Nov;17(6):1101-44.
135: Bensalah K, Crépel M, Patard JJ. Tumor size and nephron-sparing surgery: does it still
matter? Eur Urol. 2008 Apr;53(4):691-3.
136: Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S,
Karakiewicz PI. Toxicities associated with the administration of sorafenib, sunitinib, and
temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008
May;53(5):917-30.
137: Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, Perrotte P. Neoadjuvant
sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol.
2008 Apr;53(4):845-8.
138: Pouessel D, Culine S, Verhoest G, Patard JJ. [Renal cell carcinoma and antiangiogenic
therapies]. Presse Med. 2008 Apr;37(4 Pt 2):628-33.
139: Patard JJ, Verhoest G, Culine S. [Prognostic factors in localized and in metastatic renal cell
carcinomas]. Prog Urol. 2007 Sep;17(5):912-6.
140: Hutterer GC, Patard JJ, Colombel M, Belldegrun AS, Pfister C, Guille F, Artibani W,
Montorsi F, Pantuck AJ, Karakiewicz PI. Cytoreductive nephron-sparing surgery does not appear
to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer.
2007 Dec 1;110(11):2428-33.
141: Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ, Figlin RA.
Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol
Hematol. 2008 Mar;65(3):235-62.
142: Hutterer GC, Patard JJ, Jeldres C, Perrotte P, de La Taille A, Salomon L, Verhoest G,
Tostain J, Cindolo L, Ficarra V, Artibani W, Schips L, Zigeuner R, Mulders PF, Karakiewicz PI.
Patients with distant metastases from renal cell carcinoma can be accurately identified: external
validation of a new nomogram. BJU Int. 2008 Jan;101(1):39-43.
143: Karakiewicz PI, Hutterer GC, Trinh QD, Pantuck AJ, Klatte T, Lam JS, Guille F, de La Taille
A, Novara G, Tostain J, Cindolo L, Ficarra V, Schips L, Zigeuner R, Mulders PF, Chautard D,
Lechevallier E, Valeri A, Descotes JL, Lang H, Soulie M, Ferriere JM, Pfister C, Mejean A,
Belldegrun AS, Patard JJ. Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int.
2007 Oct;100(4):802-8.
144: Novara G, De Marco V, Gottardo F, Dalpiaz O, Bouygues V, Galfano A, Martignoni G,
Patard JJ, Artibani W, Ficarra V. Independent predictors of cancer-specific survival in transitional
cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
Cancer. 2007 Oct 15;110(8):1715-22.
145: Hutterer GC, Patard JJ, Perrotte P, Ionescu C, de La Taille A, Salomon L, Verhoest G,
Tostain J, Cindolo L, Ficarra V, Artibani W, Schips L, Zigeuner R, Mulders PF, Valeri A, Chautard
D, Descotes JL, Rambeaud JJ, Mejean A, Karakiewicz PI. Patients with renal cell carcinoma nodal
metastases can be accurately identified: external validation of a new nomogram. Int J Cancer. 2007
Dec 1;121(11):2556-61.
146: Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard
JJ. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a
European study of 313 patients. Cancer. 2007 Sep 15;110(6):1241-7.
147: Rioux-Leclercq N, Fergelot P, Zerrouki S, Leray E, Jouan F, Bellaud P, Epstein JI, Patard JJ.
Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a
prospective study of 50 cases. Hum Pathol. 2007 Oct;38(10):1489-95.
148: Patard JJ. [Prognostic factors in kidney cancer]. Prog Urol. 2007 Feb;17(1 Suppl 1):139-43.
149: Ficarra V, Galfano A, Guillé F, Schips L, Tostain J, Mejean A, Lang H, Mulders P, De La
Taille A, Chautard D, Descotes JL, Cindolo L, Novara G, Rioux-Leclercq N, Zattoni F, Artibani
W, Patard JJ. A new staging system for locally advanced (pT3-4) renal cell carcinoma: a
multicenter European study including 2,000 patients. J Urol. 2007 Aug;178(2):418-24;
150: Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, Abbou CC, De La Taille A,
Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Allhoff EP, Schips L,
Zigeuner R, Figlin RA, Kabbinavar FF, Pantuck AJ, Belldegrun AS, Lam JS. Prognostic impact of
tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol. 2007
Jul;178(1):35-40.
151: Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Böhm M,
Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M,
Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS,
Pantuck AJ. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance
of the primary-free interval. J Urol. 2007 Jun;177(6):2081-6.
152: Verhoest G, Manunta A, Bensalah K, Vincendeau S, Rioux-Leclercq N, Guillé F, Patard JJ.
Laparoscopic partial nephrectomy with clamping of the renal parenchyma: initial experience. Eur
Urol. 2007 Nov;52(5):1340-6.
153: Bensalah K, Rioux-Leclercq N, Vincendeau S, Guille F, Patard JJ. [Is tumour expression of
VEGF associated with venous invasion and survival in pT3 renal cell carcinoma?]. Prog Urol. 2007
Apr;17(2):189-93.
154: Chalmel F, Rolland AD, Niederhauser-Wiederkehr C, Chung SS, Demougin P, Gattiker A,
Moore J, Patard JJ, Wolgemuth DJ, Jégou B, Primig M. The conserved transcriptome in human
and rodent male gametogenesis. Proc Natl Acad Sci U S A. 2007 May 15;104(20):8346-51.
155: Klatte T, Wunderlich H, Patard JJ, Kleid MD, Lam JS, Junker K, Schubert J, Böhm M,
Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M,
Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS,
Pantuck AJ. Clinicopathological features and prognosis of synchronous bilateral renal cell
carcinoma: an international multicentre experience. BJU Int. 2007 Jul;100(1):21-5.
156: Karakiewicz PI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS, Patard JJ.
Platelet count and preoperative haemoglobin do not significantly increase the performance of
established predictors of renal cell carcinoma-specific mortality. Eur Urol. 2007 Nov;52(5):142836.
157: Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la
Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A,
Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ. Multi-institutional validation of a new
renal cancer-specific survival nomogram. J Clin Oncol. 2007 Apr 10;25(11):1316-22.
158: Guichard G, Larré S, Gallina A, Lazar A, Faucon H, Chemama S, Allory Y, Patard JJ,
Vordos D, Hoznek A, Yiou R, Salomon L, Abbou CC, de la Taille A. Extended 21-sample needle
biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol. 2007
Aug;52(2):430-5.
159: Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, Sinescu
IC; European Association of Urology Guideline Group for renal cell carcinoma. Renal cell
carcinoma guideline. Eur Urol. 2007 Jun;51(6):1502-10.
160: Verhoest G, Salomon L, Barrou B, Bensalah K, Guille F, Lobel B, Petit J, Boutin JM,
Descotes JL, Dore B, Staerman F, Benoit G, Badet L, Hubert J, Lechevallier E, Patard JJ; Comité
de Transplantation Association Française d'Urologie. [National prospective survey on the surgical
quality of renal transplants in France. Study conducted by the Association Française d'Urologie
Transplantation Committee]. Prog Urol. 2007 Feb;17(1):54-9.
161: Crepel M, Bernhard JC, Bellec L, Albouy B, Lopes D, Lacroix B, De la Taille A, Salomon L,
Pfister C, Soulie M, Tostain J, Ferriere JM, Abbou CC, Guille F, Bensalah K, Vincendeau S,
Manunta A, Colombel M, Patard JJ. [Comparison of open and laparoscopic partial nephrectomy:
a French multicentre experience]. Prog Urol. 2007 Feb;17(1):45-9.
162: Karakiewicz PI, Trinh QD, de la Taille A, Abbou CC, Salomon L, Tostain J, Cindolo L,
Artibani W, Ficarra V, Patard JJ. ECOG performance status 0 or 1 and symptom classification do
not improve the ability to predict renal cell carcinoma-specific survival. Eur J Cancer. 2007
Apr;43(6):1023-9.
163: Karakiewicz PI, Trinh QD, Rioux-Leclercq N, de la Taille A, Novara G, Tostain J, Cindolo L,
Ficarra V, Artibani W, Schips L, Zigeuner R, Mulders PF, Lechevallier E, Coulange C, Valeri A,
Descotes JL, Rambeaud JJ, Abbou CC, Lang H, Jacqmin D, Mejean A, Patard JJ. Collecting duct
renal cell carcinoma: a matched analysis of 41 cases. Eur Urol. 2007 Oct;52(4):1140-5.
164: Lam JS, Klatte T, Patard JJ, Goel RH, Guillè F, Lobel B, Abbou CC, De La Taille A,
Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Schips L, Zigeuner R,
Pantuck AJ, Figlin RA, Belldegrun AS. Prognostic relevance of tumour size in T3a renal cell
carcinoma: a multicentre experience. Eur Urol. 2007 Jul;52(1):155-62.
165: Karakiewicz P, Perrotte P, Trinh QD, Patard JJ. Rebuttal from authors re: Edward M.
Messing. Node positive renal cell cancer. Who can be helped? Eur Urol 2007;51:1477-8. Eur Urol.
2007 Jun;51(6):1478-80.
166: Guillaume H, Dillenseger JL, Patard JJ. Intra subject 3D/3D kidney registration/modeling
using spherical harmonics applied on partial information. Conf Proc IEEE Eng Med Biol Soc.
2004;3:1699-702.
167: Rioux-Leclercq N, Karakiewicz PI, Trinh QD, Ficarra V, Cindolo L, de la Taille A, Tostain J,
Zigeuner R, Mejean A, Patard JJ. Prognostic ability of simplified nuclear grading of renal cell
carcinoma. Cancer. 2007 Mar 1;109(5):868-74.
168: Patard JJ, Pantuck AJ, Crepel M, Lam JS, Bellec L, Albouy B, Lopes D, Bernhard JC, Guillé
F, Lacroix B, De La Taille A, Salomon L, Pfister C, Soulié M, Tostain J, Ferriere JM, Abbou CC,
Colombel M, Belldegrun AS. Morbidity and clinical outcome of nephron-sparing surgery in
relation to tumour size and indication. Eur Urol. 2007 Jul;52(1):148-54.
169: Karakiewicz PI, Trinh QD, Bhojani N, Bensalah K, Salomon L, de la Taille A, Tostain J,
Cindolo L, Altieri V, Ficarra V, Schips L, Zigeuner R, Mulders PF, Valeri A, Descotes JL, Mejean
A, Patard JJ. Renal cell carcinoma with nodal metastases in the absence of distant metastatic
disease: prognostic indicators of disease-specific survival. Eur Urol. 2007 Jun;51(6):1616-24.
170: Verhoest G, Veillard D, Guillé F, De La Taille A, Salomon L, Abbou CC, Valéri A,
Lechevallier E, Descotes JL, Lang H, Jacqmin D, Tostain J, Cindolo L, Ficarra V, Artibani W,
Schips L, Zigeuner R, Mulders PF, Mejean A, Patard JJ. Relationship between age at diagnosis
and clinicopathologic features of renal cell carcinoma. Eur Urol. 2007 May;51(5):1298-304;
discussion 1304-5.
171: Roulet V, Satie AP, Ruffault A, Le Tortorec A, Denis H, Guist'hau O, Patard JJ, RiouxLeclerq N, Gicquel J, Jégou B, Dejucq-Rainsford N. Susceptibility of human testis to human
immunodeficiency virus-1 infection in situ and in vitro. Am J Pathol. 2006 Dec;169(6):2094-103.
172: Cabillic F, Bouet-Toussaint F, Toutirais O, Rioux-Leclercq N, Fergelot P, de la Pintière CT,
Genetet N, Patard JJ, Catros-Quemener V. Interleukin-6 and vascular endothelial growth factor
release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk. Clin Exp
Immunol. 2006 Dec;146(3):518-23..
173: Bensalah K, Manunta A, Guillé F, Patard JJ. [Diagnosis and management of posterior
urethra disruptions]. Ann Urol (Paris). 2006 Oct;40(5):309-16. Review.
174: Patard JJ. With increasing minimally invasive options for small renal tumours, it is time to
develop patient-specific treatment strategies. Eur Urol. 2007 Apr;51(4):876-8.
175: Dillenseger JL, Guillaume H, Patard JJ. Spherical harmonics based intrasubject 3-D kidney
modeling/registration technique applied on partial information. IEEE Trans Biomed Eng. 2006
Nov;53(11):2185-93.
176: Patard JJ. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?
Eur Urol. 2006 Jul;50(1):11-3.
177: Bensalah K, Patard JJ. [Management of T1G3 tumours of the bladder]. Ann Urol (Paris).
2006 Apr;40(2):93-100.
178: Verhoest G, Rioux-Leclercq N, Guille F, Bensalah K, Lobel B, Patard JJ. Laparoscopic
management of a transitional cell carcinoma arising in a right ectopic ureter. Int J Urol. 2006
Mar;13(3):287-8.
179: Patard JJ. Renal cell carcinoma with inferior vena cava invasion: an orphan disease? Eur
Urol. 2006 Aug;50(2):208-10.
180: Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5
and caspase 8 are key players. Prostate. 2006 Jun 15;66(9):987-95.
181: Karakiewicz PI, Lewinshtein DJ, Chun FK, Briganti A, Guille F, Perrotte P, Lobel B, Ficarra
V, Artibani W, Cindolo L, Tostain J, Abbou CC, Chopin D, De La Taille A, Patard JJ. Tumor size
improves the accuracy of TNM predictions in patients with renal cancer. Eur Urol. 2006
Sep;50(3):521-8.
182: Roulet V, Denis H, Staub C, Le Tortorec A, Delaleu B, Satie AP, Patard JJ, Jégou B,
Dejucq-Rainsford N. Human testis in organotypic culture: application for basic or clinical research.
Hum Reprod. 2006 Jun;21(6):1564-75.
183: Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding the importance of smart drugs in
renal cell carcinoma. Eur Urol. 2006 Apr;49(4):633-43.
184: Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F, Patard JJ.
Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006 Mar;175(3 Pt 1):859-63.
185: Bensalah K, Sadiq A, Guillé F, Lobel B, Patard JJ. [Risks and benefits of total nephrectomy
in elderly patients over the age of 80]. Prog Urol. 2005 Sep;15(4):632-5.
186: Fendler JP, Patard JJ, Mejean A, Davin JL; Comité de Cancérologie de l'Association
Française d'Urologie. [Follow-up of renal cancer. Guidelines of the Comité de Cancérologie de
l'Association Française d'Urologie]. Prog Urol. 2005 Sep;15(4):577-81.
187: Fergelot P, Rioux-Leclercq N, Patard JJ. [Molecular pathways of tumour angiogenesis and
new targeted therapeutic approaches in renal cancer]. Prog Urol. 2005 Dec;15(6):1021-9.
188: Patard JJ. Prognostic and biological significance of lymph node spreading in renal cell
carcinoma. Eur Urol. 2006 Feb;49(2):220-2.
189: Ficarra V, Guillè F, Schips L, de la Taille A, Prayer Galetti T, Tostain J, Cindolo L, Novara
G, Zigeuner R, Bratti E, Li G, Altieri V, Abbou CC, Zanolla L, Artibani W, Patard JJ. Proposal
for revision of the TNM classification system for renal cell carcinoma. Cancer. 2005 Nov
15;104(10):2116-23.
190: Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, de La Taille A, Altieri V,
Lobel B, Zigeuner RE, Artibani W, Guillé F, Abbou CC, Salzano L, Gallo C. Comparison of
predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after
nephrectomy: a multicenter European study. Cancer. 2005 Oct 1;104(7):1362-71
191: Ficarra V, Schips L, Guillè F, Li G, De La Taille A, Prayer Galetti T, Cindolo L, Novara G,
Zigeuner RE, Bratti E, Tostain J, Altieri V, Abbou CC, Artibani W, Patard JJ. Multiinstitutional
European validation of the 2002 TNM staging system in conventional and papillary localized renal
cell carcinoma. Cancer. 2005 Sep 1;104(5):968-74
192: Gervais A, Levêque J, Bouet-Toussaint F, Burtin F, Lesimple T, Sulpice L, Patard JJ,
Genetet N, Catros-Quemener V. Dendritic cells are defective in breast cancer patients: a potential
role for polyamine in this immunodeficiency. Breast Cancer Res. 2005;7(3):R326-35.
193: Rioux-Leclercq N, Leray E, Patard JJ, Lobel B, Guillé F, Jouan F, Bellaud P, Epstein JI. The
utility of Ki-67 expression in the differential diagnosis of prostatic intraepithelial neoplasia and
ductal adenocarcinoma. Hum Pathol. 2005 May;36(5):531-5.
194: Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A,
Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PF, Wood CG,
Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histologic subtypes in
renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005 Apr 20;23(12):2763-71.
195: Cindolo L, de la Taille A, Schips L, Zigeuner RE, Ficarra V, Tostain J, Artibani W, Gallo A,
Salzano L, Patard JJ. Chromophobe renal cell carcinoma: comprehensive analysis of 104 cases
from multicenter European database. Urology. 2005 Apr;65(4):681-6.
196: Auzanneau C, Manunta A, Vincendeau S, Patard JJ, Guillé F, Lobel B. [Management of
acute prostatitis, based on a series of 100 cases]. Prog Urol. 2005 Feb;15(1):40-4.
197: Méjean A, André M, Doublet JD, Fendler JP, de Fromont M, Hélénon O, Lang H, Négrier S,
Patard JJ, Piéchaud T; Comité de Cancérologie de l'Association Française d'Urologie. [Kidney
tumors]. Prog Urol. 2004 Nov;14(4 Suppl 1):997, 999-1035.
198: Patard JJ. [Congress of the American Urological Association (AUA): update on prostate
cancer]. Ann Urol (Paris). 2004 Dec;38 Suppl 3:S69-82.
199: Manunta A, Vincendeau S, Patard JJ, Lobel B, Guillé F. [Recent traumatic injuries of the
urethra]. Ann Urol (Paris). 2004 Dec;38(6):275-84.
200: Patard JJ, Dorey FJ, Cindolo L, Ficarra V, De La Taille A, Tostain J, Artibani W, Abbou
CC, Lobel B, Chopin DK, Figlin RA, Belldegrun AS, Pantuck AJ. Symptoms as well as tumor size
provide prognostic information on patients with localized renal tumors. J Urol. 2004 Dec;172(6 Pt
1):2167-71.
201: Rioux-Leclercq N, Delcros JG, Bansard JY, Epstein JI, Patard JJ, Lobel B, Guillé F, Jouan F,
Bellaud P, Moulinoux JP. Immunohistochemical analysis of tumor polyamines discriminates high-
risk patients undergoing nephrectomy for renal cell carcinoma. Hum Pathol. 2004 Oct;35(10):127984.
202: Patard JJ, Leray E, Cindolo L, Ficarra V, Rodriguez A, De La Taille A, Tostain J, Artibani
W, Abbou CC, Guillé F, Chopin DK, Lobel B. Multi-institutional validation of a symptom based
classification for renal cell carcinoma. J Urol. 2004 Sep;172(3):858-62.
203: Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo
L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel
B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. Use of the University of California Los
Angeles integrated staging system to predict survival in renal cell carcinoma: an international
multicenter study. J Clin Oncol. 2004 Aug 15;22(16):3316-22.
204: Bensalah K, Guillé F, Vincendeau S, Rioux-Leclercq N, Manunta A, Lobel B, Patard JJ.
[Clinical and histological prognostic factors of renal cancer with caval thrombus]. Prog Urol. 2004
Apr;14(2):160-6.
205: Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La
Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF,
Belldegrun AS. Safety and efficacy of partial nephrectomy for all T1 tumors based on an
international multicenter experience. J Urol. 2004 Jun;171(6 Pt 1):2181-5.
206: Patard JJ, Tazi H, Bensalah K, Rodriguez A, Vincendeau S, Rioux-Leclercq N, Guillé F,
Lobel B. The changing evolution of renal tumours: a single center experience over a two-decade
period. Eur Urol. 2004 Apr;45(4):490-3.
207: Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, Popov Z, Zafrani ES,
Abbou CC, Chopin DK, de Medina SG. Pretreatment p53 nuclear overexpression as a prognostic
marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG). Eur Urol. 2004
Apr;45(4):475-82
208: Lobel B, Patard JJ, Guille F. [Nosocomial infections in urology]. Ann Urol (Paris). 2003
Dec;37(6):339-44.
209: Romis L, Cindolo L, Patard JJ, Messina G, Altieri V, Salomon L, Abbou CC, Chopin D,
Lobel B, de La Taille A. Frequency, clinical presentation and evolution of renal oncocytomas:
multicentric experience from a European database. Eur Urol. 2004 Jan;45(1):53-7.
210: Cindolo L, de la Taille A, Messina G, Romis L, Abbou CC, Altieri V, Rodriguez A, Patard
JJ. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003
Dec;92(9):901-5.
211: Tazi H, Manunta A, Rodriguez A, Patard JJ, Lobel B, Guillé F. Spinal cord compression in
metastatic prostate cancer. Eur Urol. 2003 Nov;44(5):527-32.
212: Saint F, Kurth N, Maille P, Vordos D, Hoznek A, Soyeux P, Patard JJ, Abbou CC, Chopin
DK. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of
superficial bladder cancer during induction course and maintenance therapy. Int J Cancer. 2003
Nov 10;107(3):434-40.
213: Rodriguez A, Tazi H, Patard JJ, Lobel B. [Renal cell carcinoma in adults less than 40 years
of age: a particular cancer? Incidence, outcome and review of the literature]. Ann Urol (Paris).
2003 Aug;37(4):155-9.
214: Vincendeau S, de Lajarte-Thirouard AS, Bensalah K, Guillé F, Lobel B, Patard JJ.
[Neuroendocrine differentiation of bladder tumors]. Prog Urol. 2003 Jun;13(3):375-84.
215: Patard JJ, Rodriguez A, Lobel B. The current status of intravesical therapy for superficial
bladder cancer. Curr Opin Urol. 2003 Sep;13(5):357-62.
216: Bouet-Toussaint F, Patard JJ, Gervais A, Genetet N, de la Pintière CT, Rioux-Leclercq N,
Toutirais O, Thirouard AS, Ramée MP, Catros-Quemener V. Cytotoxic effector cells with
antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell
carcinoma for cell therapy use. Cancer Immunol Immunother. 2003 Nov;52(11):699-707.
217: Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guillé F, Lobel B. Correlation between
symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol. 2003
Aug;44(2):226-32.
218: Hesry V, Guillaudeux T, Patard JJ. [Clinical applications of TRAIL in cancers. The prostate
cancer example]. Pathol Biol (Paris). 2003 Apr;51(3):123-8.
219: Morin G, Vincendeau S, Manunta A, Guillé F, Lobel B, Patard JJ. [Intraperitoneal bladder
rupture during transurethral resection of the prostate]. Prog Urol. 2003 Apr;13(2):303-5.
220: Vincendeau S, Abi Moussa M, Manunta A, Patard JJ, Guillé F, Lobel B. [PSA: the difficult
position of general practitioners between patients and urologists]. Prog Urol. 2003 Apr;13(2):252-5.
221: Patard JJ, Bensalah K, Vincendeau S, Rioux-Leclerq N, Guillé F, Lobel B. [Correlation
between the mode of presentation of renal tumors and patient survival]. Prog Urol. 2003
Feb;13(1):23-8.
222: Moudouni SM, Ennia I, Turlin B, Patard JJ, Guille F, Lobel B. [Carcinomatous degeneration
on augmentation ileocystoplasty for tuberculous bladder]. Ann Urol (Paris). 2003 Feb;37(1):33-5.
223: Le Goffic R, Mouchel T, Ruffault A, Patard JJ, Jégou B, Samson M. Mumps virus decreases
testosterone production and gamma interferon-induced protein 10 secretion by human leydig cells.
J Virol. 2003 Mar;77(5):3297-300.
224: Cormier L, Lechevallier E, Barrou B, Benoit G, Bensadoun H, Boudjema K, Descottes JL,
Doré B, Guy L, Malavaud B, Martin X, Patard JJ, Petit J, Salomon L. Diagnosis and treatment of
prostate cancers in renal-transplant recipients. Transplantation. 2003 Jan 27;75(2):237-9.
225: Salomon L, Colombel M, Patard JJ, Gasman D, Chopin D, Abbou CC. Prostate Biopsy in the
staging of prostate cancer. Prostate Cancer Prostatic Dis. 1997 Dec;1(2):54-58.
226: Salomon L, Colombel, Patard JJ, Herard A, Gasman D, Chopin D, Abbou CC. Eight year
improvement in pathological results after radical prostatectomy. Prostate Cancer Prostatic Dis.
1999 Jan;2(1):21-24.
227: Ziade J, Leprise ES, Bansard JY, Patard JJ, Lobel B, Guille F. Prostate specific antigen
levels in the follow up of localised prostate cancer: how does radiotherapy compare to radical
prostatectomy? Prostate Cancer Prostatic Dis. 1999 May;2(3):155-158.
228: Patard JJ, Bensalah K, Lucas A, Rodriguez A, Manunta A, Rivalan J, Le Pogamp P, Lobel
B, Guillé F. Management of vascular access for hemodialysis after successful kidney
transplantation. Scand J Urol Nephrol. 2002;36(5):373-6.
229: Moudouni S, En-Nia I, Rioux-Leclerq N, Bensalah K, Guille F, Lobel B, Patard JJ. [Renal
cell carcinoma before the age of 40: prognostic factors]. Prog Urol. 2002 Sep;12(4):575-8.
230: Rodríguez A, Patard JJ, Lobel B. Renal cell carcinoma in young adults: incidence, disease
outcome and review of the literature. Arch Esp Urol. 2002 Oct;55(8):969-75.
231: Moudouni SM, En-Nia I, Patard JJ, Manunta A, Guillé F, Lobel B. Real indications for
adrenalectomy in renal cell carcinoma. Scand J Urol Nephrol. 2002;36(4):273-7.
232: Patard JJ, Rodriguez A, Rioux-Leclercq N, Guillé F, Lobel B. Prognostic significance of the
mode of detection in renal tumours. BJU Int. 2002 Sep;90(4):358-63..
233: Patard JJ, Bouet F, Rioux-Leclercq N, Lobel B, Catros-Quemener V, Guillé F. [Local
immune tolerance mechanisms in kidney cancer]. Prog Urol. 2002 Apr;12(2):205-12.
234: Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guillé F, Lobel B. Intravesical Bacillus
Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol. 2002
Jun;41(6):635-41.
235: Mouchel T, Le Goffic R, Patard JJ, Samson M. [Mumps virus and orchitis: towards a
physiopathologic approach]. Prog Urol. 2002 Feb;12(1):124-8.
236: Le Goffic R, Mouchel T, Aubry F, Patard JJ, Ruffault A, Jégou B, Samson M. Production of
the chemokines monocyte chemotactic protein-1, regulated on activation normal T cell expressed
and secreted protein, growth-related oncogene, and interferon-gamma-inducible protein-10 is
induced by the Sendai virus in human and rat testicular cells. Endocrinology. 2002
Apr;143(4):1434-40
237: Yiou R, Patard JJ, Benhard H, Abbou CC, Chopin DK. Outcome of radical cystectomy for
bladder cancer according to the disease type at presentation. BJU Int. 2002 Mar;89(4):374-8.
238: Karmouni T, Bensalah K, Alva A, Patard JJ, Lobel B, Guillé F. [Role of antibiotic
prophylaxis in ambulatory cystoscopy]. Prog Urol. 2001 Dec;11(6):1239-41.
239: Moudouni SM, En-Nia I, Patard JJ, Guille F, Lobel B. [Spontaneous subcapsular renal
hematoma: diagnosis and treatment. Two case reports]. Ann Urol (Paris). 2002 Jan;36(1):29-32.
240: Moudouni S, En-Nia I, Rioux-Leclerc N, Patard JJ, Guillé F, Lobel B. [Renal metastasis of
thyroid carcinoma]. Prog Urol. 2001 Sep;11(4):670-2.
241: Karmouni T, Patard JJ, Bensalah K, Manunta A, Guillé F, Lobel B. [Urologic management
of ureteral iatrogenic lesions]. Prog Urol. 2001 Sep;11(4):642-6.
242: Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK.
Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus CalmetteGuerin treatment for superficial bladder cancer. J Urol. 2002 Jan;167(1):364-7.
243: Rioux-Leclercq N, Epstein JI, Bansard JY, Turlin B, Patard JJ, Manunta A, Chan T, Ramee
MP, Lobel B, Moulinoux JP. Clinical significance of cell proliferation, microvessel density, and
CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol. 2001 Nov;32(11):120915.
244: Moudouni SM, Hadj Slimen M, Manunta A, Patard JJ, Guiraud PH, Guille F, Bouchot O,
Lobel B. Management of major blunt renal lacerations: is a nonoperative approach indicated? Eur
Urol. 2001 Oct;40(4):409-14.
245: Manunta A, Patard JJ, Guillé F, Moussa MA, Morin G, Guiraud P, Lobel B. Recurrent
pyelonephritis without vesicoureteral reflux: is there a role for an antireflux procedure? J Endourol.
2001 Sep;15(7):707-10.
246: Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, De La Taille A, Abbou CC,
Chopin DK. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding
patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol.
2001 Dec;166(6):2142-7.
247: Saint F, Patard JJ, Groux Muscatelli B, Lefrere Belda MA, Gil Diez de Medina S, Abbou
CC, Chopin DK. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder
wall after bacillus Calmette-Guérin treatment. BJU Int. 2001 Oct;88(6):602-10.
248: Patard J, Moudouni S, Saint F, Rioux-Leclercq N, Manunta A, Guy L, Ballanger P, Lanson
Y, Hajri M, Irani J, Guillé F, Beurton D, Lobel B; Bernard Lobel and The members of the Groupe
Necker. Tumor progression and survival in patients with T1G3 bladder tumors: multicentric
retrospective study comparing 94 patients treated during 17 years. Urology. 2001 Oct;58(4):551-6.
249: Soulié M, Salomon L, Patard JJ, Mouly P, Manunta A, Antiphon P, Lobel B, Abbou CC,
Plante P. Extraperitoneal laparoscopic pyeloplasty: a multicenter study of 55 procedures. J Urol.
2001 Jul;166(1):48-50.
250: Moudouni SM, En-Nia I, Patard JJ, Lobel B, Guillé F. [Arterial embolization
hemorrhagic renal angiomyolipoma]. Prog Urol. 2001 Apr;11(2):235-8.
in
251: Bensalah K, Guillé F, Rivalan J, Joyeux V, Gié S, Laruelle E, Garry J, Morin MP, Le Pogamp
P, Lobel B, Patard JJ. [Natural history of vascular ports for hemodialysis after renal
transplantation]. Prog Urol. 2001 Apr;11(2):231-4.
252: Saint F, Irani J, Patard JJ, Salomon L, Hoznek A, Zammattio S, Debois H, Abbou CC,
Chopin DK. Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder
cancer. Urology. 2001 May;57(5):883-8.
253: Moudouni SM, Patard JJ, Manunta A, Guiraud P, Lobel B, Guillé F. Early endoscopic
realignment of post-traumatic posterior urethral disruption. Urology. 2001 Apr;57(4):628-32.
254: Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, Debois H, Abbou CC, Chopin
DK. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy
for superficial bladder cancer. Urology. 2001 Apr;57(4):617-21.
255: Moudouni SM, Patard JJ, Manunta A, Guiraud P, Guille F, Lobel B. A conservative
approach to major blunt renal lacerations with urinary extravasation and devitalized renal segments.
BJU Int. 2001 Mar;87(4):290-4
256: Saint F, Patard JJ, Salomon L, Alamé W, Cicco A, Abbou CC, Chopin D. [Mechanisms of
action of BCG: towards a new individualized therapeutic approach?]. Prog Urol. 2000
Dec;10(6):1118-26.
257: Karmouni T, Rioux-Leclercq N, Bensalah K, Alva A, Patard JJ, Guillé F, Lobel B. [Primary
neuroendocrine carcinoma of the bladder: diagnosis and treatment]. Prog Urol. 2000
Sep;10(4):590-4.
258: Pupca G, Patard JJ, Ziadé J, Guiraud P, Lobel B, Guillé F. [Symptom scores: what do they
describe exactly?]. Prog Urol. 2000 Sep;10(4):561-7.
259: Rioux-Leclercq N, Le Gall F, Ziade J, Patard JJ, Guille F, Lobel B, Ramee MP.
[Intraluminal renal metastasis from a rectal adenocarcinoma: an unusual site]. Ann Pathol. 2000
Sep;20(4):361-4.
260: Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard
JJ, Lesimple T, Catros-Quemener V. Interleukin-2 expanded lymphocytes from lymph node and
tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur Cytokine Netw. 2000
Jun;11(2):217-24.
261: Rioux-Leclercq N, Staerman F, Patard JJ, Billerey C, Guillé F, Lobel B, Ramée MP.
[Unusual variety of bladder urothelial carcinoma: "nest type" microlobular carcinoma: report of an
anatomoclinical case and review of the literature]. Ann Urol (Paris). 2000 Feb;34(1):9-12.
262: Rioux-Leclercq N, Turlin B, Bansard J, Patard J, Manunta A, Moulinoux JP, Guillé F,
Ramée MP, Lobel B. Value of immunohistochemical Ki-67 and p53 determinations as predictive
factors of outcome in renal cell carcinoma. Urology.
263: Manunta A, Guillé F, Patard JJ, Lobel B. Artificial sphincter insertion after radiotherapy: is
it worthwhile? BJU Int. 2000 Mar;85(4):490-2.
264: Benhard H, Patard JJ, Salomon L, Pollux C, Chopin D, Abbou CC. [Studer's bladder:
functional results and morbidity in 33 patients]. Prog Urol. 1999 Dec;9(6):1062-6.
265: el Khader K, Guille F, Mhidia A, Ziade J, Patard JJ, Lobel B. [Urological complications of
endometriosis]. Ann Urol (Paris). 1999;33(2):80-3. French.
266: Salomon L, Saporta F, Amsellem D, Hozneck A, Colombel M, Patard JJ, Chopin D, Abbou
CC. Results of pyeloureterostomy after ureterovesical anastomosis complications in renal
transplantation. Urology. 1999 May;53(5):908-12.
267: el Khader K, Guillé F, Mhidia A, Ziadé J, Patard JJ, Lobel B. [Bologna procedure in stress
urinary incontinence with stage III cystocele (with or without vaginal hysterectomy)]. Prog Urol.
1999 Feb;9(1):81-7
268: Saporta F, Salomon L, Amsellem D, Patard JJ, Hozneck A, Colombel M, Chopin D, Abbou
C. [Results of pyeloureteral anastomoses onto the native ureter after complication of ureterovesical
anastomosis in kidney transplantation]. Prog Urol. 1999 Feb;9(1):47-51.
269: Yiou R, Salomon L, Colombel M, Patard JJ, Chopin D, Abbou CC. Perineal approach to
radical prostatectomy in kidney transplant recipients with localized prostate cancer. Urology. 1999
Apr;53(4):822-4.
270: Salomon L, Colombel M, Patard JJ, Lefrère-Belda MA, Bellot J, Chopin D, Abbou CC.
Value of ultrasound-guided systematic sextant biopsies in prostate tumor mapping. Eur Urol. 1999
Apr;35(4):289-93.
271: el Khader K, Mhidia A, Ziade J, Patard JJ, Guille F, Lobel B. [Conservative treatment of
stage III kidney injuries]. Acta Urol Belg. 1998 Dec;66(4):25-8.
272: el Kahder K, Guille F, Patard JJ, Mhidia A, Ziade J, Manunta A, Lobel B. [Ureteral
reimplantation on psoas bladder: long-term results]. Acta Urol Belg. 1998 Dec;66(4):15-20.
273: Salomon L, Colombel M, Patard JJ, Bellot J, Chopin DK, Abbou CC. Use of three additional
mid biopsies to improve local assessment of prostate cancer in patients with one positive sextant
biopsy. Eur Urol. 1998 Oct;34(4):313-7.
274: Patard JJ, Chopin D, Abbou CC. [Treatment of superficial tumors of the bladder]. Cancer
Radiother. 1998 Apr;2 Suppl 1:19s-26s.
275: Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK. Immune response following
intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res.
1998;26(3):155-9.
276: Patard JJ, Guillé F, Lobel B, Abbou CC, Chopin D. [Current state of knowledge concerning
the mechanisms of action of BCG]. Prog Urol. 1998 Jun;8(3):415-21.
277: Salomon L, Herard A, Colombel M, Patard JJ, Bellot J, Lefrere-Belda MA, Hoznék A,
Gasman D, Chopin D, Abbou CC. [Improvement over time of oncological results after radical
prostatectomy: what are the responsible factors?]. Prog Urol. 1998 Jun;8(3):363-9.
278: el Khader K, Ziadé J, Bansard JY, Mhidia A, Patard JJ, Guillé F, Lobel B. [Outcome of renal
function in 114 patients who underwent uninephrectomy for renal cancer]. Prog Urol. 1998
Jun;8(3):341-6.
279: Guéguen M, Patard JJ, Gaugler B, Brasseur F, Renauld JC, Van Cangh PJ, Boon T, Van den
Eynde BJ. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol.
1998 Jun 15;160(12):6188-94.
280: Salomon L, Colombel M, Patard JJ, Lefrére-Belda MA, Bellot J, Gasman D, Hoznek A,
Chopin D, Abbou CC. [The value of prostatic biopsy in tumor mapping]. Prog Urol. 1998
Apr;8(2):217-22.
281: Salomon L, Colombel M, Patard JJ, Chopin D, Abbou CC. [Prostatic specific antigen in
practice in 1997]. Ann Urol (Paris). 1998;32(2):69-72.
282: Joual A, Patard JJ, Chopin D, Abbou CC. [Contralateral aneurysm-like adrenal gland
metastasis of a renal adenocarcinoma]. Prog Urol. 1998 Feb;8(1):89-91.
283: Salomon L, Colombel M, Patard JJ, Contremoulins I, Bellot J, Lefrére-Belda MA, Gasman
D, Chopin D, Abbou CC. [Retropubic and perineal approach: plea for perineal radical
prostatectomy]. Prog Urol. 1997 Dec;7(6):976-83.
284: Salomon L, Colombel M, Patard JJ, Bellot J, Vogt B, Lefrère-Belda MA, Chopin D, Abbou
CC. [Volume and spatial representation of tumors in the core of the prostate gland]. Prog Urol.
1997 Jun;7(3):442-8.
285: Patard JJ, Muscatelli-Groux B, Saint F, Popov Z, Maille P, Abbou C, Chopin D. Evaluation
of local immune response after intravesical bacille Calmette-Guérin treatment for superficial
bladder cancer. Br J Urol. 1996 Nov;78(5):709-14.
286: Barthélémy Y, Colombel M, Gasman D, Patard JJ, Chopin D, Abbou CC. [Antiandrogen
withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
Prog Urol. 1996 Feb;6(1):93-7.
287: Patard JJ. [Hematuria: current strategies]. Ann Urol (Paris). 1996;30(6-7):274-5.
288: Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T,
Schrier P, Van den Eynde BJ. A new gene coding for an antigen recognized by autologous cytolytic
T lymphocytes on a human renal carcinoma. Immunogenetics. 1996;44(5):323-30.
289: Patard JJ, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, François P, Abi-Aad A, Van
Cangh P, Abbou CC, Chopin D, et al. Expression of MAGE genes in transitional-cell carcinomas
of the urinary bladder. Int J Cancer. 1995 Feb 20;64(1):60-4.
290: Patard JJ, Chopin DK, Abbou CC. [BCG therapy. Its role in the treatment of tumors of the
bladder]. Ann Urol (Paris). 1995;29(5):292-3.
291: Ravery V, Colombel M, Popov Z, Bastuji S, Patard JJ, Bellot J, Abbou CC, Fradet Y,
Chopin DK. Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in
bladder cancer. Br J Cancer. 1995 Jan;71(1):196-200.
292: Hermieu JF, Van Glabeke E, Patard JJ, Baron JC, Abecassis R, Anidjar M, Delmas V,
Boccon-Gibod L. [Endoscopic retropubic colpopexy for stress urinary incontinence in women
(Stamey's operation). 55 cases]. Prog Urol. 1994 Feb;4(1):63-9.
293: Patard JJ, Desgrandchamps F, Ollier P, Duffas JP, Cussenot O, Teillac P, Le Duc A. [The
value of MRI in ruptures of the corpus cavernosum]. Prog Urol. 1993 Dec;3(6):1024-7. French.
PubMed PMID: 8305931.
294: Patard JJ, Abbou C, Chopin D. [Research analysis of local immune response after
intravesicular treatment with BCG: a review]. Prog Urol. 1993 Oct;3(5):745-51. Review.
295: Patard JJ, Chopin D. [Survey of instillation methods of BCG in the preventive treatment of
superficial tumors of the bladder. Subcommittee of Superficial Tumors of the Bladder, the
Committee of Cancerology of the French Association of Urology]. Prog Urol. 1993 AugSep;3(4):590-4.
296: Patard JJ, Chopin DK. [Preventive treatment of superficial tumors of the bladder using
intravesical BCG. Review]. Ann Urol (Paris). 1993;27(1):24-30.
297: Patard JJ, Chopin DK, Boccon-Gibod L. Mechanisms of action of bacillus Calmette-Guérin
in the treatment of superficial bladder cancer. World J Urol. 1993;11(3):165-8.
298: Chopin DK, Popov Z, Ravery V, Bellot J, Hoznek A, Patard JJ, Abbou CC, Colombel M.
Prognostic factors in superficial bladder cancer. World J Urol. 1993;11(3):148-52.